Table 3 Antimicrobial exposure of patients with MC-CRBSI events
From: Surveillance of catheter-related infections: the supplementary role of the microbiology laboratory
Number of antimicrobials a patient had been exposed to % (n = 57) | |
|---|---|
None | 5.3 (3) |
1 | 21.1 (12) |
2 | 33.3 (19) |
3 | 15.8 (9) |
4 | 8.8 (5) |
5 | 7.0 (4) |
6 | 3.5 (2) |
Unknown | 5.3 (3) |
Antimicrobial agents, according to class, to which patients were exposed to # % (n = 131 exposure events) | |
Carbapenems | 29.8 (39) |
Glycopeptides | 15.3 (20) |
Polymyxins (colistin) | 10.7 (14) |
Antifungals | 9.9 (13) |
β-lactamase inhibitors (piperacillin/tazobactam) | 6.9 (9) |
Penicillin | 4.6 (6) |
Folate pathway inhibitors | 3.8 (5) |
Oxazolidnones (linezolid) | 3.8 (5) |
Aminoglycosides | 3.1 (4) |
Extended-spectrum cephalosporins | 3.1 (4) |
Non extended-spectrum cephalosporins | 3.1 (4) |
Rifampicin | 2.3 (3) |
β-lactamase inhibitors (amoxicillin/clavulanic acid) | 1.5 (2) |
Rifafour | 0.8 (1) |
Macrolides | 0.8 (1) |
Glycylcyclines (tigecycline) | 0.8 (1) |